Revumenib
Merck inks US$ 3.3 bn cancer deal with LaNova; vaccine makers’ stocks tumble after Trump picks RFK Jr to head HHS

Merck inks US$ 3.3 bn cancer deal with LaNova; vaccine makers’ stocks tumble after Trump picks RFK Jr to head HHS

This week, Merck struck a strategic US$ 3.3 billion deal with LaNova Medicines for a promising cancer drug, and also demonstr...

Impressions : 1971